global biotech investing: "vertex verkaufen"... warum????? - 500 Beiträge pro Seite

[Toni21]

hi vertex aktionäre. ich bin bestimmt nicht der einzige der vertex im depot hat und von der aktie überzeugt hat.....warum schreibt GLOBAL BIOTECH INVESTING vertex verkaufen???? seite 2. angeblich übernahmeangebot unterbreitet worden. phantasie soll draussen sein.....
WAS SAGT IHR. und der aktionär schreibt in seiner ausgabe 43 seite71: wir bleiben VORERST weiter dabei!

zu guter letzt. nennt mir bitte eure biotech -aktien mit dem grössten kurspotenzial.

ciao... toni

[Rainolaus]

Das sind ja ganz neue Töne zu diesem super, super "Langfrist"-Wert. Langfristig heisst beim Aktionär oft ~3 Monate.
Werden schlechte Zahlen am 25.10. erwartet? Hatte eigentlich überlegt nachzukaufen. Jetzt muß ich erst mal neu recherchieren, was da los sein könnte.

R.

[Rainolaus]

Die beste Biotech Aktie ist für mich:

DWS Biotech Typ 0

Ist irgendwie sicherer mit einem Fonds, wenn man nicht den ganzen Tag auf seine Werte aufpassen kann. Es sind nur gute, große Werte drin. Wenn einer Scheiße baut. Was soll´s. Der Rest steigt, außer der ganze Index geht runter.

Als Einzelwert finde ich Sequenom (932193) als "Schaufelbauer" ganz gut.

[kartoffeleis]

Nur die Ruhe! Kaufsignal vom MACD gerade erst generiert. Doublebottom mit Kurs über EMA20, Aufwärtstrend bestätigend, und nicht zuletzt: Förstch und Frick halten VERTEX weiterhin im 3Sat-Konkurrenzdepot, und da möchten die beiden Herren doch bestimmt nicht schlecht aussehen!

[kartoffeleis]

Und am Freitag nachbörslich + 1/4 $ damit Kurs behauptet.

[Rainolaus]

Phanatsie bei Vertex draussen? Sind aber echt wechselhaft die Analysten, oder nur `ne Profilneurose.
Gibt es auch kritische (Pro)-Meinungen zu o.g. Analystenstimmen?

[Dark]

was denn für ne übernahme??????????????

[genya]

für alle, die einen relativ kurzen anlagehorizont haben:
Vertex, wie die meisten Biotechs, werden in kürze eine korrektur durchmachen, da von der letzten an der nasdaq verschont und die meisten anleger diese erwarten und hypernervös sind. Bin selber bei vrtx drin und sehe das ganze kurzfristig gar nicht so rosig ( gott gebe was dafür daß ich mich irre).
Auf der anderen seite gibts extrem viele neu aufgelegte Biotechfonds, und der geldzufluss steigt jeden tag, wei bios "sexy" seien.
Und der beste indikator ist old bernie, der fast nur noch auf biotechs setzt - er war einer der ersten, der die potentiale von I-nets erkannt hat, man soll über ihn urteilen, wie man will, aber eine
gute "nase" hat er...

[Toni21]

ich hab keine ahnung was für eine übernahme!!!!!!steht im GLOBAL BIOTECH INVESTING!!!!!! wo steht das 3sat depot von förtsch??

[pinzer]

Verkaufen, jetzt??

Press Release
SOURCE: Vertex Pharmaceuticals Incorporated

Vertex Expands Product Pipeline with Selection of Four New Drug Candidates Targeting Viral Infections, Autoimmune and Inflammatory Diseases, and Cardiovascular Disorders
CAMBRIDGE, Mass., Oct. 23 /CNW/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - news) announced today the expansion of its product pipeline with the selection of four new drug candidates with the potential to treat viral infections, autoimmune diseases, cardiovascular disorders and inflammation. The selection of these candidates reflects the successful completion of Vertex research programs focused on the discovery of second- generation, small molecule inhibitors of IMPDH, p38 MAP kinase, and interleukin-1 beta converting enzyme (ICE). Each drug candidate that has been selected is now undergoing formal preclinical development in preparation for the start of clinical studies. Two or more of the newly selected drug candidates are expected to enter Phase I clinical studies in 2001.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO )

"These new drug candidates are strong evidence of the productivity gains we have been able to achieve in drug discovery," said Joshua Boger, Ph.D, Chairman, President, and CEO of Vertex. "They represent the leading edge of our accelerated research output from our integrated drug discovery platform and our chemogenomics approach. We believe that our increased speed and success in translating genomic discoveries into product candidates will create enhanced commercial and business development opportunities for Vertex, allowing us to expand our pipeline and create value for shareholders."

New Drug Candidates Targeting IMPDH

Vertex announced today the selection of VX-944 as a new drug development candidate from the Company`s IMPDH research program. Earlier in 2000, Vertex advanced another IMPDH inhibitor, VX-148, into preclinical development. Clinical development of VX-148 is expected to begin in early 2001. Vertex`s most advanced IMPDH inhibitor, VX-497, is in Phase II clinical development in combination with interferon alpha for the treatment of hepatitis C virus infection. All three compounds are potent inhibitors of IMPDH (inosine monophosphate dehydrogenase), a cellular enzyme that is essential for production of guanine nucleotides, one of the building blocks of RNA and DNA. Blocking IMPDH may be an effective strategy for blocking the proliferation (growth) of certain cell types, such as lymphocytes, and the replication of viruses, since both lymphocytes and viruses depend on nucleotide synthesis for replication. Vertex`s IMPDH inhibitors have the potential to treat viral infections, autoimmune diseases, and prevent organ transplant rejection. Vertex has retained all development and commercial rights to drug candidates in its IMPDH program.

New Drug Candidates Targeting p38 MAP Kinase

Vertex announced today the selection of VX-954 and VX-702 as new drug development candidates from the Company`s p38 MAP kinase research program. P38 MAP kinase is an enzyme that regulates the production of interleukin-1 beta, interleukin-6 (IL-6) and tumor necrosis factor alpha, which are involved in acute and chronic inflammatory response. Inhibition of p38 MAP kinase may be an effective strategy for slowing the progression of acute and chronic inflammatory reactions. As part of a collaboration with Vertex, Kissei Pharmaceutical Co., Ltd. holds an option to develop VX-954 and VX-702 in Japan and other Far East countries. Vertex`s p38 MAP kinase inhibitors have the potential to treat a range of inflammatory and cardiovascular diseases. Vertex`s most advanced p38 MAP kinase inhibitor, VX-745, is in Phase II clinical development in collaboration with Kissei for the treatment of rheumatoid arthritis.

New Drug Candidate Targeting ICE

Vertex announced today the selection of VX-765 as a new drug development candidate from the Company`s ICE research program. ICE is an enzyme that regulates the production of IL-1 and IFN gamma, intercellular mediators that initiate and sustain the process of inflammation. Inhibiting ICE may be an effective strategy for curtailing damaging inflammatory processes common to a number of acute and chronic conditions. Vertex`s most advanced ICE inhibitor, VX-740, is in Phase II clinical development for the treatment of rheumatoid arthritis as part of a worldwide collaboration with Aventis S.A. Vertex`s ICE inhibitors have the potential to treat a range of inflammatory, cardiovascular, and neurological diseases. Vertex retains development and commercial rights to VX-765 and other drug candidates that may be selected from the Company`s second-generation ICE research program.

The drug candidates announced today represent classes of compounds that are distinct from first-generation inhibitors designed by Vertex that are now in clinical development. Each was chosen from among several lead candidates that met stringent criteria for selection, including potency, bioavailability, half-life, ease-of-synthesis, and preclinical indicators of safety. Each drug candidate has demonstrated a therapeutic effect in two or more models of disease activity.

"The five drug candidates we have advanced this year reflect a sustained ramp-up in drug discovery productivity, and provide us the opportunity to pursue multiple indications based on common mechanisms of action," said Vicki Sato, Ph.D., Senior Vice President of Research and Development and Chief Scientific Officer. "In 2001, we anticipate the selection of new drug development candidates targeting caspases, bacterial gyrase, hepatitis C protease, neurophilins, and kinases. This puts Vertex on track to double the size of our product development pipeline, increasing the number of products in development from eight to approximately 16 by the end of next year."

Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex now has 12 drug candidates in development to treat viral diseases, inflammation, cancer, autoimmune diseases and cardiovascular and neurological disorders. Vertex has created its pipeline using a proprietary, information-intensive approach to drug design that integrates multiple technologies in biology, chemistry and biophysics, aimed at increasing the speed and success rate of drug discovery. Vertex`s first approved product is Agenerase(TM) (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with Glaxo Wellcome.

This press release contains forward looking statements about Vertex and some of its potential drug development candidates, including statements regarding the expected timing of clinical development activities and the selection of additional new drug development candidates, the therapeutic potential and the commercial and business development opportunities for our drug development candidates, and the expansion of Vertex`s product development pipeline. While management makes its best efforts to be accurate in making forward-looking statements, any such statements are subject to risks and uncertainties that could cause actual results to vary materially. These risks include the possibility of delays in clinical trials as a result of delays in planned patient enrollment among other things, the risk that clinical trials may not result in a marketable product, and the risk that Vertex may be unable to successfully finance, secure regulatory approval of and market any of its current or future drug candidates.

Vertex`s press releases are available at www.vrtx.com, or by fax-on-demand at [phone] - Code: 938395

Quelle: yahoo.com

pinzer

[jako98]

waere super wenn einer den bericht übersetzen könnte danke im voraus

[heikolino]

lese ich da richtig?
große ausweitung der produktpipeline?
quasi verdopplung?
gruß

[measii]

@Toni 21
www.Muster-Depot.de

[MLFI]

Hi
Versteh eure Panik nicht ganz? Heute Vertex in Amerika auf 913?4 das ist ein Plus von 15% sollte man jetzt aussteigen oder warten? Hier ein Bericht und da schreiben sie ganz positiv:
Marktkommentar:

Zeigte der Biotech-Index in der Vorwoche aus charttechnischer Sicht noch leicht negative Tendenzen, so wurden diese spätestens in der letzten Woche deutlich zum Positiven gewandelt. Deutlich konnte der IXBT-Biotechindex die 200-Tagelinie wieder hinter sich lassen und so den charttechnischen Abgabedruck zur Seite schieben.

Am Freitag schloss der IXBT-Biotechindex bei 1.239 Punkten und damit rund 100 Punkte über dem Stand der Vorwoche. Dies entspricht einem Anstieg über die Woche hinweg von rund 9,5 %.

Zumindest aus charttechnischer Sicht scheint der Index die 1.300 Punkte Marke anzupeilen. Wir zumindest gehen davon aus, dass bei einer ähnlich guten Nachrichtenlage diese Marke kein Problem darstellen sollte.

Bitte um Antwort
MLFi

[Steuerfrei]

Hallo

Ich bin der Meinung, daß GBI dort ein Fehler unterlaufen ist. Sollte Vertex wirklich ein
Übernahmeangebot unterbreitet worden sein, hätte es sicherlich eine Pressemitteilung gegeben.
Vertex wird meines Erachtens weiter ein Outperformer bleiben. Das bestätigen auch wieder
die letzten beiden News. Warten wir einfach mal die Zahlen heute Abend ab.
Entweder werden wir ein "Sell on good News" sehen oder sie setzen ihr Ziel, die Alltimehighs
zu knacken, wieder fort.

Stay long

Steuerfrei


PS: Hier noch die zweite News die ich meinte. Die erste steht ja schon weiter oben im Thread.



Vertex and Glaxo Wellcome`s New Anti-HIV Medicine, Agenerase(TM)
(Amprenavir), Approved in the European Union

CAMBRIDGE, Mass., Oct. 23 /CNW/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - news) announced today
that its collaborator, Glaxo Wellcome, has received approval from the European Commission to market the HIV protease inhibitor (PI) Agenerase (amprenavir), in
all 15 countries of the European Union. Agenerase is indicated in combination with other anti- retroviral agents, for the treatment of PI-experienced HIV-infected
adults and children above 4 years of age. In connection with today`s announcement, Vertex will receive a $3 million milestone payment from Glaxo Wellcome,
payable in the fourth quarter of 2000.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000119/VERTEXLOGO )

Agenerase will be available as soft capsules and as oral solution. Unlike most currently marketed PIs, Agenerase has a twice-daily dosing regimen without any food
or water restrictions.

Agenerase is currently approved and marketed in Argentina, Brazil, Chile, Colombia, Ghana, Israel, Mexico, Switzerland, Uruguay, and the United States.
Amprenavir is also approved in Japan where it is marketed by Vertex`s partner Kissei Pharmaceutical Co., Ltd. under the trade name Prozei(TM).

Amprenavir was discovered by scientists at Vertex Pharmaceuticals of Cambridge, MA and licensed to Glaxo Wellcome in the United States, Europe, and other
countries. Glaxo Wellcome has been responsible for product formulation and manufacture of Agenerase, design and implementation of clinical trials, and regulatory
submissions. Glaxo Wellcome will market Agenerase in the European Union and Vertex will co-promote the drug in certain countries, where permitted by law.

Glaxo Wellcome is a research-based company whose people are committed to fighting disease by bringing innovative medicines and services to patients throughout
the world and to healthcare providers who serve them.

Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. Vertex has 12 drug
candidates in development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a
proprietary, information-intensive approach to drug design that integrates multiple technologies in biology, chemistry and biophysics, aimed at increasing the speed
and success rate of drug discovery. Vertex`s first approved product is Agenerase(TM) (amprenavir), an HIV protease inhibitor, which Vertex co-promotes with
Glaxo Wellcome.

This press release contains forward-looking statements about Vertex and Glaxo Wellcome`s product, Agenerase, including statements about the use of Agenerase
as a treatment option for patients who have failed previous PI therapy, and Glaxo Wellcome`s ability to effectively market and sell Agenerase in the European
Union. While management makes its best efforts to be accurate in making forward-looking statements, any such statements are subject to risks and uncertainties
that could cause Vertex`s actual results to vary materially. Risk factors include uncertainties relating to Glaxo Wellcome`s ability to effectively market and sell
Agenerase in the European Union, Vertex`s ability to protect its proprietary technologies, patent-infringement claims, and competitive technologies and drugs.

Agenerase is a trademark of the Glaxo Wellcome group of companies.